Is Beam Therapeutics Gaining or Losing Market Support? - Beam Therapeutics ( NASDAQ:BEAM )
Beam Therapeutics's BEAM short interest as a percent of float has fallen 6.25% since its last report. According to exchange reported data, there are now 25.48 million shares sold short, which is 28.49% of all regular shares that are available for trading.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
Cathie Wood Loads Up On Bullish Inc, Pony AI And Robinhood - Dumps Kratos Defense Amid Taiwan Drone Buzz - ARK Autonomous Technology & Robotics ETF ( BATS:ARKQ ) , ARK Innovation ETF ( BATS:ARKK )
On Wednesday, Cathie Wood-led Ark Invest executed significant trades involving Bullish BLSH, Kratos Defense and Security Solutions Inc. KTOS, Pony AI Inc. PONY, and Robinhood Markets Inc. HOOD.
Cathie Wood's Reshuffle Tuesday: Loads Up On AMD, Figma And Bullish, Trims Tempus AI - Grayscale Bitcoin Mini Trust ( BTC ) Common units of fractional undivided beneficial interest ( ARCA:BTC )
On Tuesday, Cathie Wood-led Ark Invest executed significant trades, including buying shares of Advanced Micro Devices Inc. AMD and Bullish Inc. BLSH, while selling shares of Tempus AI Inc. TEM. Additionally, Ark purchased Figma Inc. FIG stock, reflecting strategic adjustments in its investment ...
Why Is Allogene Therapeutics ( ALLO ) Up 9.4% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
1 Reason Every Investor Should Know About CRISPR Therapeutics ( CRSP )
This little company's scientific breakthrough opened up a whole new sliver of the drug market (although it's still leading the developmental race).
Can CRSP's In Vivo Pipeline Aid Long-Term Growth Beyond Casgevy?
CRISPR Therapeutics pushes beyond Casgevy with in vivo programs like CTX310, CTX320 and plans for two more studies by 2025-end.
CRSP vs. BEAM: Which Gene Editing Stock Holds More Potential Right Now?
CRISPR Therapeutics gains momentum with Casgevy sales and a broader pipeline, while Beam Therapeutics advances base-editing therapies still in early stages.
What Does the Market Think About Beam Therapeutics? - Beam Therapeutics ( NASDAQ:BEAM )
Beam Therapeutics's BEAM short percent of float has risen 4.04% since its last report. The company recently reported that it has 24.62 million shares sold short, which is 27.53% of all regular shares that are available for trading.
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences - Beam Therapeutics ( NASDAQ:BEAM )
CAMBRIDGE, Mass., Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc. BEAM, a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:
CRISPR Therapeutics Gains 41.4% in 3 Months: How to Play the Stock
CRSP surges 41.4% in three months, fueled by promising CTX310 study data and accelerating Casgevy sales.
Cathie Wood's $21 Million Tuesday Move: Peter Thiel's Crypto Play Gets Boost In Ark Portfolio - Grayscale Bitcoin Mini Trust ( BTC ) Common units of fractional undivided beneficial interest ( ARCA:BTC )
Cathie Wood-led Ark Invest made significant trades on Tuesday with notable activity in Bullish BLSH, Robinhood Markets Inc. HOOD, and Tempus AI Inc. TEM. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started
Cathie Wood's 'Apocalypse Squad' Play? Ark Scoops Up $14.2 Million Worth Of Robinhood Stock - ARK Autonomous Technology & Robotics ETF ( BATS:ARKQ ) , ARK Innovation ETF ( BATS:ARKK )
Ark Invest, led by Cathie Wood, executed notable trades on Monday, focusing on Robinhood Markets Inc. HOOD and Deere & Co. DE. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started Interactive BrokersTrade global markets with low costs and pro-level tools at ...
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease - Pfizer ( NYSE:PFE )
Inclacumab fails to reduce VOC rates in sickle cell patients in Phase 3 trial. Pfizer will continue developing its broader sickle cell portfolio. Get the latest proven ETF strategies to target and profit from summer volatility before the next big market swing. Pfizer Inc.
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings?
CRSP's Casgevy records a 114% sales jump sequentially in Q2, fueling optimism for sustained revenues and long-term growth.
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark
Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.
Beam Therapeutics Inc. ( BEAM ) Reports Q2 Loss, Misses Revenue Estimates
Beam Therapeutics (BEAM) delivered earnings and revenue surprises of +3.85% and -38.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
WALTHAM, Mass., July 31, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) , today announced its second quarter 2025 financial results and business highlights.
Vir Biotechnology, Inc. ( VIR ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Vir Biotechnology (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech ...
Will Beam Therapeutics Inc. ( BEAM ) Report Negative Q2 Earnings? What You Should Know
Beam Therapeutics (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Beam Therapeutics ( BEAM ) Surges 5.7%: Is This an Indication of Further Gains?
Beam Therapeutics (BEAM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Innovation ETF ( ARKK ) Hits New 52-Week High
Cathie Wood's ARKK hits a 52-week high after bold biotech moves, signaling renewed momentum in disruptive tech.
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global ...
3 Promising Genomics Stocks to Keep an Eye On in 2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
Cathie Wood Doubles Down On Shopify, Buys The Dip - Dumps $4.6 Million Worth Of Robinhood Stock At Peak - ARK Fintech Innovation ETF ( BATS:ARKF ) , ARK Innovation ETF ( BATS:ARKK )
Cathie Wood-led Ark Invest made notable trades on Wednesday, focusing on Shopify Inc. SHOP and Robinhood Markets Inc. HOOD.
Cathie Wood Drops $6.5 Million On SHOP And ABNB, Betting You Won't Stop Shopping Or Traveling - ARK Fintech Innovation ETF ( BATS:ARKF ) , Airbnb ( NASDAQ:ABNB )
Cathie Wood-led Ark Invest made significant trades on Tuesday, spotlighting its strategic acquisitions of Shopify Inc. SHOP and Airbnb Inc. ABNB. These trades reflect Ark's continued interest in high-growth technology and e-commerce sectors.
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Eli Lilly ( NYSE:LLY ) , Verve Therapeutics ( NASDAQ:VERV )
Eli Lilly offered a 115% premium for Verve, signaling a major vote of confidence in gene editing platforms. HC Wainwright and William Blair downgraded Verve after the deal. Last Chance: See the "Power Pattern" That Delivered Winners 9 Out of the Last 10 Summers. Get The Details Here
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led to massive shareholder returns. Editas Medicine ( NASDAQ: EDIT ) is a promising clinical-stage company that has captured Wall Street's attention at the ...
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease ( SCD ) at European Hematology Association ( EHA ) 2025 Congress
Updated Data from 17 Patients Consistent with Previously Presented Data. All Patients Treated with BEAM-101 Achieved Hemoglobin F ( HbF ) Induction of >60%, Hemoglobin S ( HbS ) Reduction to <40%, and Resolution of Anemia ...
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.
Beam Therapeutics ( BEAM ) Up 5.7% Since Last Earnings Report: Can It Continue?
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?
CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease - Beam Therapeutics ( NASDAQ:BEAM )
CAMBRIDGE, Mass., June 03, 2025 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc.
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency ( AATD ) - Beam Therapeutics ( NASDAQ:BEAM )
CAMBRIDGE, Mass., May 29, 2025 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc.
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
BMRN and NVAX are in the spotlight this week following announcement agreement and regulatory update.
3 Top Genomics Stocks to Add to Your Portfolio in 2025
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively.
Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition - Prime Medicine ( NASDAQ:PRME )
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively.
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association ( EHA ) 2025 Congress
Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of ...
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference - Beam Therapeutics ( NASDAQ:BEAM )
CAMBRIDGE, Mass., May 13, 2025 ( GLOBE NEWSWIRE ) -- Beam Therapeutics Inc. BEAM, a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference ...
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates
PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.
